Pennsylvania is currently home to 3311 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796
Recruiting
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Register for Updates
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
NCT03609216
Recruiting
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates
North American Comfilcon A Clinical Study
NCT06902584
Recruiting
The main objective of this study is to demonstrate acceptable safety and effectiveness (performance) of comfilcon A Sphere, Toric, Multifocal, Toric Multifocal and Energys lenses, when used in the general population.
Gender:
ALL
Ages:
Between 8 years and 75 years
Trial Updated:
03/27/2025
Locations: Nittany Eye Associates, College, Pennsylvania
Conditions: Astigmatism, Presbyopia, Ametropia
Register for Updates
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842
Recruiting
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/27/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Cutaneous Venous Malformations
Register for Updates
Effect of Raised End-Tidal pCo2 on Choroidal Volume
NCT06275308
Recruiting
This study is to investigate the relationship between arterial carbon dioxide (CO2) concentration and vitreous pressure on the choroidal volume by integrated intraoperative OCT imaging under eye exams under anesthesia.
Gender:
ALL
Ages:
8 years and below
Trial Updated:
03/27/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Intraocular Pressure
Register for Updates
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
NCT06070350
Recruiting
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/27/2025
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Conditions: Hemorrhagic Shock, Trauma Injury
Register for Updates
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
NCT05758545
Recruiting
The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device through 24 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.
Gender:
ALL
Ages:
Between 22 years and 90 years
Trial Updated:
03/27/2025
Locations: UPMC McKeesport, McKeesport, Pennsylvania
Conditions: Diabetic Foot Ulcer
Register for Updates
Trial of Ixazomib for Kaposi Sarcoma
NCT04305691
Recruiting
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Kaposi Sarcoma, Skin
Register for Updates
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
NCT02305654
Recruiting
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provi... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Register for Updates
Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty
NCT06792539
Recruiting
The goal of this clinical trial is to evaluate the safety and effectiveness of the Polymotion Hip Resurfacing (PHR) System compared to total hip arthroplasty, for adults who require hip resurfacing arthroplasty due to 1) non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, or 2) mild dysplasia/developmental dislocation of the hip (DDH) up to Crowe Grade 1.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/26/2025
Locations: Rothman Institute, Philadelphia, Pennsylvania
Conditions: Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Register for Updates
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
NCT06625398
Recruiting
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Scheie Eye Institute Penn Presbyterian, Philadelphia, Pennsylvania
Conditions: Thyroid Eye Disease
Register for Updates